Cerity Partners LLC Purchases 661 Shares of Illumina, Inc. (NASDAQ:ILMN)

Cerity Partners LLC grew its position in Illumina, Inc. (NASDAQ:ILMN) by 2.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 25,951 shares of the life sciences company’s stock after acquiring an additional 661 shares during the quarter. Cerity Partners LLC’s holdings in Illumina were worth $2,059,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Royal London Asset Management Ltd. boosted its holdings in Illumina by 3.2% during the 4th quarter. Royal London Asset Management Ltd. now owns 67,155 shares of the life sciences company’s stock valued at $8,974,000 after acquiring an additional 2,073 shares during the period. Lee Danner & Bass Inc. purchased a new stake in shares of Illumina in the 4th quarter worth $48,000. Virtu Financial LLC purchased a new stake in shares of Illumina in the 4th quarter worth $1,173,000. American Century Companies Inc. lifted its holdings in shares of Illumina by 11.5% in the 4th quarter. American Century Companies Inc. now owns 226,852 shares of the life sciences company’s stock worth $30,314,000 after buying an additional 23,338 shares during the period. Finally, Sei Investments Co. lifted its holdings in shares of Illumina by 3.6% in the 4th quarter. Sei Investments Co. now owns 134,913 shares of the life sciences company’s stock worth $18,028,000 after buying an additional 4,738 shares during the period. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $96.14 on Monday. The business’s fifty day moving average price is $89.22 and its two-hundred day moving average price is $94.68. The stock has a market cap of $15.22 billion, a PE ratio of -15.84, a price-to-earnings-growth ratio of 1.88 and a beta of 1.36. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.48 and a current ratio of 1.86. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.96 by $0.01. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business had revenue of $1.04 billion for the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter last year, the firm earned $0.98 earnings per share. The business’s revenue was down 1.4% on a year-over-year basis. On average, analysts forecast that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Citigroup cut Illumina from a “hold” rating to a “strong sell” rating and lowered their target price for the stock from $85.00 to $80.00 in a report on Wednesday, July 9th. Stephens reissued an “overweight” rating and issued a $105.00 price target on shares of Illumina in a research report on Tuesday, May 20th. Morgan Stanley reduced their price target on Illumina from $136.00 to $100.00 and set an “equal weight” rating for the company in a research report on Monday, May 12th. Evercore ISI boosted their price target on Illumina from $116.00 to $128.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 8th. Finally, Scotiabank lowered Illumina from a “sector outperform” rating to a “sector perform” rating and set a $125.00 price target for the company. in a research report on Friday, July 11th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $125.11.

Insider Transactions at Illumina

In other news, CFO Ankur Dhingra bought 6,100 shares of the business’s stock in a transaction on Monday, May 12th. The shares were bought at an average cost of $81.21 per share, with a total value of $495,381.00. Following the purchase, the chief financial officer directly owned 24,906 shares in the company, valued at $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.17% of the stock is currently owned by company insiders.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.